Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤채옥 | - |
dc.date.accessioned | 2022-12-09T06:45:05Z | - |
dc.date.available | 2022-12-09T06:45:05Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.citation | Molecular Therapy - Oncolytics, v. 25, Page. 78-97 | en_US |
dc.identifier.issn | 2372-7705;2372-7705 | en_US |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S237277052200050X?via%3Dihub | en_US |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/178116 | - |
dc.description.abstract | Oncolytic viruses (OVs) have emerged as a very promising anti-cancer therapeutic strategy in the past decades. However, despite their pre-clinical promise, many OV clinical evaluations for cancer therapy have highlighted the continued need for their improved delivery and targeting. Mesenchymal stromal cells (MSCs) have emerged as excellent candidate vehicles for the delivery of OVs due to their tumor-homing properties and low immunogenicity. MSCs can enhance OV delivery by protecting viruses from rapid clearance following administration and also by more efficiently targeting tumor sites, consequently augmenting the therapeutic potential of OVs. MSCs can function as “biological factories,” enabling OV amplification within these cells to promote tumor lysis following MSC-OV arrival at the tumor site. MSC-OVs can promote enhanced safety profiles and therapeutic effects relative to OVs alone. In this review we explore the general characteristics of MSCs as delivery tools for cancer therapeutic agents. Furthermore, we discuss the potential of OVs as immune therapeutics and highlight some of the promising applications stemming from combining MSCs to achieve enhanced delivery and anti-tumor effectiveness of OVs at different pre-clinical and clinical stages. We further provide potential pitfalls of the MSC-OV platform and the strategies under development for enhancing the efficacy of these emerging therapeutics. | en_US |
dc.description.sponsorship | BioRender was utilized to design some of the figures. This research was supported by grants from the National Research Foundation of Korea ( 2016M3A9B5942352 and 2021R1A2C301016611 , C.-O.Y.), and we also would like to acknowledge support from a Purdue Research Foundation research grant (C.R.-C.), NIH CA153165 and in part CA196947 (M.L.F.) funding, and support from the College of Veterinary Medicine and the Department of Basic Medical Sciences at Purdue University . | en_US |
dc.language | en | en_US |
dc.publisher | Cell Press | en_US |
dc.source | 84468_윤채옥.pdf | - |
dc.subject | enhanced delivery | en_US |
dc.subject | immunotherapy | en_US |
dc.subject | mesenchymal stromal cells | en_US |
dc.subject | metastatic tumors | en_US |
dc.subject | oncolytic viruses | en_US |
dc.title | Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors | en_US |
dc.type | Article | en_US |
dc.relation.volume | 25 | - |
dc.identifier.doi | 10.1016/j.omto.2022.03.008 | en_US |
dc.relation.page | 78-97 | - |
dc.relation.journal | Molecular Therapy - Oncolytics | - |
dc.contributor.googleauthor | Yoon, A-Rum | - |
dc.contributor.googleauthor | Rivera-Cruz, Cosette | - |
dc.contributor.googleauthor | Gimble, Jeffrey M. | - |
dc.contributor.googleauthor | Yun, Chae-Ok | - |
dc.contributor.googleauthor | Figueiredo, Marxa L. | - |
dc.sector.campus | S | - |
dc.sector.daehak | 공과대학 | - |
dc.sector.department | 생명공학과 | - |
dc.identifier.pid | chaeok | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.